Clinical Trials Logo

Recurrent Prostate Cancer clinical trials

View clinical trials related to Recurrent Prostate Cancer.

Filter by:

NCT ID: NCT00058214 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Perifosine in Treating Patients With Recurrent Prostate Cancer

Start date: March 2003
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent prostate cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00058084 Completed - Clinical trials for Adenocarcinoma of the Prostate

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Start date: March 2003
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying ixabepilone to see how well it works compared to mitoxantrone and prednisone in treating patients with metastatic prostate cancer that has not responded to paclitaxel, docetaxel, or hormone therapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Ixabepilone may reduce resistance to the drugs and allow the tumor cells to be killed. It is not yet known which chemotherapy regimen is more effective in treating metastatic prostate cancer

NCT ID: NCT00040755 Completed - Bone Metastases Clinical Trials

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Start date: May 2002
Phase: Phase 2
Study type: Interventional

BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therapy

NCT ID: NCT00039104 Completed - Clinical trials for Adenocarcinoma of the Prostate

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Start date: April 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.

NCT ID: NCT00031681 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

NCT ID: NCT00030498 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Start date: December 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

NCT ID: NCT00020046 Completed - Clinical trials for Adenocarcinoma of the Prostate

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Start date: December 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or without thalidomide in treating patients who have metastatic prostate cancer.

NCT ID: NCT00019695 Terminated - Bone Metastases Clinical Trials

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Start date: March 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium. PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.

NCT ID: NCT00016107 Completed - Clinical trials for Adenocarcinoma of the Prostate

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Start date: June 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab may stop the growth of cancer cells by stopping blood flow to the tumor. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.

NCT ID: NCT00005067 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

Start date: February 2000
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of photodynamic therapy with lutetium texaphyrin in treating patients with locally recurrent prostate cancer. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for locally recurrent prostate cancer. Photosensitizing drugs, such as lutetium texaphyrin, are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells